×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OVID – ovid therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OVID
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
08:09 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Medium
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
12/2
08:07 am
ovid
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
Neutral
Report
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting [Yahoo! Finance]
12/2
08:00 am
ovid
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
Low
Report
Ovid Therapeutics to Present Multiple Posters Supporting Its Pipeline Programs Targeting Neuronal Hyperexcitability at the American Epilepsy Society 2024 Annual Meeting
11/12
11:02 am
ovid
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/12
08:00 am
ovid
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Medium
Report
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
10/31
08:00 am
ovid
Ovid Therapeutics to Host Investor Event
Low
Report
Ovid Therapeutics to Host Investor Event
9/30
12:18 pm
ovid
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? [Yahoo! Finance]
Low
Report
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely? [Yahoo! Finance]
9/30
08:01 am
ovid
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
Ovid Therapeutics Inc. (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
12/16
04:16 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Friedman Bart
Low
Report
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Friedman Bart
12/16
04:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Duncan Barbara Gayle
Low
Report
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Duncan Barbara Gayle
12/16
04:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Bernstein Karen
Low
Report
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Bernstein Karen
12/16
04:15 pm
ovid
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Fitzgerald Kevin Joseph
Low
Report
Form 4 Ovid Therapeutics Inc. For: Dec 12 Filed by: Fitzgerald Kevin Joseph
11/14
06:02 pm
ovid
Form SC 13G/A Ovid Therapeutics Inc. Filed by: EcoR1 Capital, LLC
High
Report
Form SC 13G/A Ovid Therapeutics Inc. Filed by: EcoR1 Capital, LLC
11/14
04:40 pm
ovid
Form SC 13G/A Ovid Therapeutics Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A Ovid Therapeutics Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
11/12
09:26 am
ovid
Form 8-K Ovid Therapeutics Inc. For: Nov 12
High
Report
Form 8-K Ovid Therapeutics Inc. For: Nov 12
11/12
09:26 am
ovid
Form 10-Q Ovid Therapeutics Inc. For: Sep 30
High
Report
Form 10-Q Ovid Therapeutics Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/24
Form 8-K Ovid Therapeutics Inc. For: Sep 23
25.5%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
6/18 Form 8-K Ovid Therapeutics Inc. For: Jun 18 14.2%
11/29 RBC bullish on OVID's 2020 catalysts [Seeking Alpha] 10.4%
9/23 Form 8-K Ovid Therapeutics Inc. For: Sep 23 10.3%
8/17 Ovid Therapeutics Inc (NASDAQ: OVID) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock. 9.8%
7/1 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at Cowen Inc. 9.6%
7/18 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 9.4%
10/10 Form 4 Ovid Therapeutics Inc. For: Oct 08 Filed by: LEVIN JEREMY M 7.5%
11/15 Form 4 Ovid Therapeutics Inc. For: Nov 13 Filed by: Bernstein Karen 6.6%
12/20 Form 4 Ovid Therapeutics Inc. For: Dec 18 Filed by: Perone Thomas Michael 6.0%
TOP News Decliners
3/12
Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
-28.1%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
10/3 Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock -26.8%
3/11 Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020 -18.8%
3/6 Ovid Therapeutics Inc (NASDAQ: OVID) had its "buy" rating re-affirmed by analysts at LADENBURG THALM/SH SH. They now have a $20.00 price target on the stock. -13.4%
5/7 Q1/2019 3/31/2019 EPS -0.460 ZacksConsensus N/A ActVsEst N/A - N/A -11.3%
6/27 Form 8-K Ovid Therapeutics Inc. For: Jun 27 -7.5%
9/26 Ovid Therapeutics Inc (NASDAQ: OVID) was given a new $14.00 price target on by analysts at Piper Jaffray Companies. They now have a "buy" rating on the stock. -6.9%
2/14 Form SC 13G/A Ovid Therapeutics Inc. Filed by: LEVIN JEREMY M -6.8%
11/4 Form 4 Ovid Therapeutics Inc. For: Nov 01 Filed by: Daly Timothy -5.9%
8/22 Ovid Therapeutics Inc (NASDAQ: OVID) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: